Amgen: Low LDL Levels With Repatha Did Not Affect Cognitive Function In Study – Nasdaq
NPR Amgen: Low LDL Levels With Repatha Did Not Affect Cognitive Function In StudyNasdaq(RTTNews.com) – Amgen Inc. ( AMGN ) announced results from the Repatha or evolocumab cognitive function trial (EBBINGHAUS) evaluating the impact on cognitive function in 1,974 patients enrolled in the Repatha cardiovascular outcomes study, …Cholesterol drug cuts heart risks, spurs new debate on … Read more